Background: Rituximab is a monoclonal antibody, targeting CD20 on surface of B lymphocytes. It is used in the treatment of various of haematologic conditions. Rituximab treatment is associated with rapid and prolonged B-cell depletion, reduced humoral response and secondary hypogammaglobulinemia. Recovery from which may take up to 12 months, therefore patients who receive rituximab are at increased risk of infectious complications for a long period of time after treatment. Aims: To evaluate the potential impact of prior rituximab therapy on clinical outcomes of COVID-19 infection. Methods: We conducted a retrospective study on haematology patients who received rituximab from December 2019 to October 2021 and were diagnosed with COVID-19 pneumonia. Indications of rituximab were treatment of lymphoma, CLL, and autoimmune haematological disorders. Results: 139 were included in the study. Of these 139 patients, 13 got admitted to the hospital. The reason for hospitalization of patients was severe COVID-19 pneumonia and its complications. Median age was (71.5) years. 5 patients (38.4%) developed severe COVID-19 that ultimately led to their deaths. Mean admission days was (10.5) days. Median time between rituximab and COVID-19 infection was 3.9 months. 5 patients had ITU admissions, 8 had oxygen support, one was discharged on home oxygen. 2 of the patients who died received anti-SARS-CoV-2 monoclonal antibodies which did not seem to improve the condition. Summary/Conclusion: There is no doubt that COVID-19 pandemic presents unprecedented challenge to haematologist and patients receiving rituximab.Our observed mortality in hospitalised patients indicates that a significant proportion of haematology patients recover and survive despite recent rituximab treatment. Further studies including larger cohort of patients are essential to validate that rituximab can be safely delivered for haematology patients. Dose modification regimens, and effects on long term disease control remain to be clarified.